Nkarta said it expects initial data from a clinical trial testing its cell therapy candidate NKX019 in adults with ANCA-associated vasculitis (AAV) and other autoimmune diseases to be presented later this year. The Phase 1/2 Ntrust-2 trial (NCT06733935) is testing several doses of NKX019 in up to…
Discussion
In our ANCA vasculitis community, the real F-word is fatigue. And I need to say something about it plainly: What we experience is definitely not the tiredness that healthy people know. Fatigue in vasculitis is not just sleepiness. It is not the grogginess after a bad night’s sleep…
People with ANCA-associated vasculitis (AAV) are more likely to have worse kidney function and related outcomes if their self-targeting antibodies, called ANCAs, activate immune cells via the Fc gamma receptor protein, a study suggested. “[Fc gamma-driven] ANCA can be a biomarker for poor kidney prognosis in ANCA-associated vasculitis,” the…
Becoming educated and informed about ANCA vasculitis is a good first step. Here you’ll find general information such as the diagnosis, symptoms, and causes.
It helps to know others have been where you are now. Here’s a collection of our columnists’ words of wisdom to help you along on your ANCA vasculitis journey.
There is no cure for ANCA vasculitis yet, but here you can find more information about current approved treatments, as well as experimental treatments that are in the pipeline.
Get regular updates to your inbox.
